Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16998
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJohnson, Stephanie-
dc.contributor.authorClayton, Josephine M-
dc.contributor.authorButow, Phyllis N-
dc.contributor.authorSilvester, William-
dc.contributor.authorDetering, Karen M-
dc.contributor.authorHall, Jane-
dc.contributor.authorKiely, Belinda E-
dc.contributor.authorCebon, Jonathan S-
dc.contributor.authorClarke, Stephen-
dc.contributor.authorBell, Melanie L-
dc.contributor.authorStockler, Martin R-
dc.contributor.authorBeale, Phillip-
dc.contributor.authorTattersall, Martin HN-
dc.date2016-12-01-
dc.date.accessioned2017-12-08T03:13:27Z-
dc.date.available2017-12-08T03:13:27Z-
dc.date.issued2016-12-01-
dc.identifier.citationBMJ Open 2016; 6(12): e012387en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16998-
dc.description.abstractINTRODUCTION: There is limited evidence documenting the effectiveness of Advance Care Planning (ACP) in cancer care. The present randomised trial is designed to evaluate whether the administration of formal ACP improves compliance with patients' end-of-life (EOL) wishes and patient and family satisfaction with care. METHODS AND ANALYSIS: A randomised control trial in eight oncology centres across New South Wales and Victoria, Australia, is designed to assess the efficacy of a formal ACP intervention for patients with cancer. Patients with incurable cancer and an expected survival of 3-12 months, plus a nominated family member or friend will be randomised to receive either standard care or standard care plus a formal ACP intervention. The project sample size is 210 patient-family/friend dyads. The primary outcome measure is family/friend-reported: (1) discussion with the patient about their EOL wishes and (2) perception that the patient's EOL wishes were met. Secondary outcome measures include: documentation of and compliance with patient preferences for medical intervention at the EOL; the family/friend's perception of the quality of the patient's EOL care; the impact of death on surviving family; patient-family and patient-healthcare provider communication about EOL care; patient and family/friend satisfaction with care; quality of life of patient and family/friend subsequent to trial entry, the patient's strength of preferences for quality of life and length of life; the costs of care subsequent to trial entry and place of death. ETHICS AND DISSEMINATION: Ethical approval was received from the Sydney Local Health District (RPA Zone) Human Research Ethical Committee, Australia (Protocol number X13-0064). Study results will be submitted for publication in peer-reviewed journals and presented at national and international conferences. TRIAL REGISTRATION NUMBER: Pre-results; ACTRN12613001288718.en_US
dc.subjectAdvance Directiveen_US
dc.subjectAdvance care planningen_US
dc.subjectEnd of Lifeen_US
dc.subjectRandomised controlled trialen_US
dc.titleAdvance care planning in patients with incurable cancer: study protocol for a randomised controlled trialen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBMJ Openen_US
dc.identifier.affiliationCentre for Medical Psychology and Evidence-based Decision-making (CeMPED), School of Psychology, University of Sydney, Sydney, New South Wales, Australiaen_US
dc.identifier.affiliationDepartment of Cancer Medicine, University of Sydney, Sydney, New South Wales, Australiaen_US
dc.identifier.affiliationHammondCare Palliative and Supportive Care Service, Greenwich Hospital, Sydney, New South Wales, Australiaen_US
dc.identifier.affiliationKolling Institute of Medical Research, Northern Clinical School, University of Sydney, Sydney, New South Wales, Australiaen_US
dc.identifier.affiliationAdvance Care Planning Department, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationCentre for Health Economics Research and Evaluation, University of Technology, Sydney, New South Wales, Australiaen_US
dc.identifier.affiliationNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australiaen_US
dc.identifier.affiliationLudwig Institute for Cancer Research, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Medical Oncology, Royal North Shore Hospital Sydney, Sydney, New South Wales, Australiaen_US
dc.identifier.affiliationMel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona, USAen_US
dc.identifier.affiliationDepartment of Medical Oncology, Sydney Local Health District (SLHD) and Royal Prince Alfred Hospital (RPA), Sydney, New South Wales, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27909034en_US
dc.identifier.doi10.1136/bmjopen-2016-012387en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
local.name.researcherCebon, Jonathan S
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptAdvance Care Planning-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

26
checked on Nov 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.